Home
Seattle Genetics

Seattle Genetics Market Share Analysis for November 2025

discover the commonalities and differences between biologics vs. biosimilars — especially when it comes to cost.

Health > Biotechnology and Pharmaceuticals

Domainseattlegenetics.com

Year Founded1998

Employees1001 - 5000

Annual Revenue--

Seattle Genetics

Seattle Genetics (including company regionals)

seattlegenetics.com

See more website traffic and engagement information

Total visits to Seattle Genetics's top domains

Understand Seattle Genetics market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Seattle Genetics's top domains

Analyze Seattle Genetics engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Seattle Genetics's top domains

See how Seattle Genetics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Seattle Genetics top competitors by domain

Top similar sites in November 2025, ranked by their affinity

immunogen.comCompany NameImmunoGenEmployees501 - 1000HQUnited States, Massachusetts, WalthamAnnual revenue$200M - $500MTotal visits--Health > Biotechnology and Pharmaceuticals

Top technologies used by Seattle Genetics

These are the website technologies, by industry, used by Seattle Genetics top domains

Audio Video Media (2)

Vimeo

Content Management System (2)

Web Dot Com

Mobile (2)

Meta Viewport

Widget (2)

reCAPTCHA

More Technologies

5

See all

News & Signals from Seattle Genetics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSeattle Genetics is developing novel biologics.The company has collaborated with several pharmaceutical giants, including AstraZeneca, Sanofi, and Seattle Genetics, to develop and commercialize novel biologics.

NewsPfizer Inc acquires Seattle Genetics for $43B.That pipeline will broaden as Pfizer is has agreed to acquire Seagen (NASDAQ: SGEN ) for $43 billion.

NewsSeattle Genetics is developing novel antibody-coupled T-cell receptor therapies for cancer on Jan 1st '15.Seattle Genetics, Inc. and Unum Therapeutics, Inc. in 2015 entered into a strategic collaboration and license agreement to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer.